Brufau-Cochs et al., in a review in 2024, showed that sphingosine-1-phosphate receptor modulators such as fingolimod are associated with a higher risk of basal cell carcinoma but not squamous cell carcinoma or melanoma [14]. This evidence concerns the gene S1PR1 and squamous cell carcinoma.